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Abstract
The past 50 years have seen the development of many new options for treating and preventing 
type 2 diabetes. Despite this success, the individual and societal burden of the disease continues 
unabated. Thus, the next 50 years will be critical if we are going to quell the major non-
communicable disease of our time. The knowledge we will gain in the next few years from clinical 
studies will inform treatment guidelines with regard to which agents to use in whom and whether 
more aggressive approaches can slow the development of hyperglycaemia in those at high risk. 
Beyond that, we anticipate identification of novel targets and techniques for therapeutic 
intervention. These advances will lead to more personalised approaches to treatment. Most 
importantly, we will need to focus our political and economic efforts on enhancing and 
implementing public health approaches aimed at prevention of diabetes and its co-morbidities. 
This is one of a series of commentaries under the banner ‘50 years forward’, giving personal 
opinions on future perspectives in diabetes, to celebrate the 50th anniversary of Diabetologia 
(1965–2015).
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Introduction
The rise in the prevalence of obesity has contributed to the dramatic increase in the number 
of cases of type 2 diabetes being observed in all strata of society around the globe. The basis 
for this is a gene–environment interaction in which beta cell dysfunction, typically on the 
background of insulin resistance, is critical for the increase in glucose levels observed in 
impaired glucose metabolism and for the development of the hyperglycaemia of type 2 
diabetes [1]. As reducing the extent of hyperglycaemia decreases the rate of development of 
microvascular complications and may benefit cardiovascular outcomes, ensuring adequate 
glucose control is essential. Preventing the disease would be better still. Over the past 50 
years we have seen tremendous advances in therapy for type 2 diabetes; the next 50 years 
promise to be even more interesting and will hopefully have a greater impact on diabetes.
History of approaches to the treatment of type 2 diabetes—from then to 
now
Following the first use of insulin as a therapeutic agent in 1922, there has been steady 
progress, with the introduction of eleven new classes of agents for treating hyperglycaemia 
in type 2 diabetes over the past half-century or so (Fig. 1). In addition, a number of modified 
insulins have been approved for the same purpose.
Over this period we have also witnessed the development of algorithms advising on how 
best to approach patients with hyperglycaemia. The EASD, in partnership with the ADA, 
currently recommend that metformin be the staple approach and the choice of second agents 
be individualised [2]. In addition, given the results of a host of studies examining 
approaches for diabetes prevention, both lifestyle and metformin are recommended in 
individuals at high risk of the disease, although the latter has not received formal approval 
from regulatory authorities. And with these approaches, one must not lose sight of treating 
co-existing conditions such as dyslipidaemia and hypertension.
Despite the giant strides forward over the last 50 years, it should not be forgotten that one 
size does not fit all. This is important, not only in terms of choices for the individual patient, 
but also when one considers healthcare systems around the world where many patients do 
not have access to all the different medications.
Future prospects for the treatment of type 2 diabetes—looking forward 50 
years
While we now have numerous classes of oral agents and injectables with variable 
effectiveness in lowering glucose, we have learned that they are not capable of preventing 
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progression of the beta cell lesion of type 2 diabetes [3]. In fact, the greater prevalence of 
severe insulin resistance linked to morbid obesity has prompted the development of more 
concentrated insulins that are now frequently required to maintain glucose control. We need 
novel therapies that are not only potent in terms of their capability of normalising glucose, 
but also have the ability to slow the progression of the disease. Furthermore, in an ideal 
world they would produce weight loss or, at worst, be weight neutral. For the remainder of 
this commentary we examine some of what we would expect to see in the next five decades 
as we strive to reduce the toll of type 2 diabetes.
Ongoing clinical trials
There are currently a number of clinical trials at stages varying from recruitment to near 
completion. These have been designed in response to the need for better approaches to 
prevent diabetes, for the determination of best choices when considering second-line therapy 
following metformin, and to demonstrate cardiovascular safety.
In a little over the past decade, it has been clearly demonstrated that we can slow the 
development of type 2 diabetes in those at high risk. Major studies performed worldwide 
clearly demonstrate that it is possible to slow the development of frank diabetes, with 
lifestyle intervention reducing the risk by up to 58%. Metformin and the thiazolidinediones 
have been the most effective medications, with the latter arguably being more effective than 
lifestyle. What we have also learned is that normalising glucose for even a brief period while 
intervening to prevent diabetes will halve the rate of progression to diabetes relative to that 
if normoglycaemia is never achieved [4]. With this in mind, a consortium in the USA is 
undertaking the Restoring Insulin Secretion (RISE) study, examining the relative 
effectiveness of medications in adults (metformin alone, liraglutide plus metformin, and 
glargine followed by metformin, all vs placebo), medications in children (metformin alone, 
and glargine followed by metformin), and laparoscopic gastric band surgery vs metformin in 
adults [5]. The primary goal is to determine whether aggressive lowering of glucose levels 
can prevent the loss of beta cell function that characterises the transition from impaired 
glucose tolerance to diabetes. Importantly, participants in the medications studies will be 
treated for 12 months and studied at the end of active treatment and again after a 3 month 
medication washout period to determine whether improvements in beta cell function can be 
maintained when the active intervention is no longer in place. Should RISE find one or more 
interventions to be promising, it is likely that a larger clinical trial will follow.
As mentioned previously, the EASD and ADA have developed recommendations for 
treating patients with type 2 diabetes [2]; the choices recommended are based in part on 
studies performed by the pharmaceutical industry for registering their compounds. However, 
there are inadequate head-to-head comparisons of many of the different classes of 
compounds. The Glycemia Reduction Approaches in Diabetes: A Comparative 
Effectiveness Study (GRADE) will directly compare one representative medication from 
four different classes: sulfonylureas (glimepiride), dipeptidyl peptidase-4 (DPP-4) inhibitors 
(sitagliptin), glucagon-like peptide-1 (GLP-1) receptor agonists (liraglutide) and basal 
insulins (glargine) in a long-term clinical trial in patients with diabetes for 10 years or less 
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[6]. One would hope that thorough evaluation of the comparative effectiveness over years of 
treatment with these medications will follow, to inform clinical decision-making.
Following the controversy regarding the potential increase in cardiovascular risk associated 
with thiazolidinedione therapy, regulatory authorities now require large studies to 
demonstrate the cardiovascular safety of newly developed glucose-lowering medications. 
These clinical trials require inclusion of many patients who are at high risk of, or have 
already had, a cardiovascular event. A few studies have already reported, with many more to 
come. Two trials of DPP-4 inhibitors, namely, Saxagliptin Assessment of Vascular 
Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)–Thrombolysis in 
Myocardial Infarction (TIMI) 53 and Examination of Cardiovascular Outcomes with 
Alogliptin versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute 
Coronary Syndrome (EXAMINE), showed no increased risk of major adverse 
cardiovascular events [7, 8]. Since many had touted a potential cardiovascular benefit of 
compounds acting through the incretin system, the findings in this regard were somewhat 
disappointing. Additional safety assessments conducted as part of this programme identified 
an increased risk of hospitalisation for heart failure with saxagliptin; however, it is unclear 
whether this is a class effect or not. Further studies with other DPP-4 inhibitors will provide 
more information on these issues. One of these studies, the Cardiovascular Outcome Study 
of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes (CAROLINA), will also 
test whether linagliptin has a safer cardiovascular profile than the sulfonylurea glimepiride, 
providing further information related to the long-standing controversy regarding 
sulfonylurea safety, which was initially raised by the University Group Diabetes Program in 
the 1970s [9]. In addition to these studies, others examining the safety of GLP-1 receptor 
agonists, sodium–glucose co-transporter 2 (SGLT2) inhibitors and new long-acting insulins 
are on the horizon. While some have questioned the cost–benefit of these large safety 
studies, we earnestly request that the companies undertaking these trials make the data 
available for further analyses and subsequent publication, as they will provide rich data on 
both medication safety and efficacy, as well as the natural history of diabetes.
New therapies—new targets and beyond
Our understanding of the pathogenesis of type 2 diabetes continues to drive the 
identification of novel and new therapeutic targets. These targets are located in the 
‘traditional’ organs, comprised of the liver, fat, muscle and pancreatic islet, and more 
recently the ‘non-traditional’ targets, including the intestine, kidney, brain, macrophage and 
adrenal gland (Fig. 1). Those listed in the figure as possibilities for the period ‘2015–2065’ 
are those currently known by the authors as being pursued, but do not represent all 
possibilities. For example, as the understanding of the role of the brain in regulating 
metabolism broadens, it is likely that a number of central targets will emerge. Importantly, 
we must develop interventions to stop or reverse the loss of beta cell function and mass. 
Thiazolidinediones have, to date, been the most effective approach [3], most likely because 
they reduce ‘afterload’ on the beta cell and thereby decrease secretory demand and slow 
disease progression. That said, new approaches are needed. Some novel targets may be 
identified from studies addressing the mechanisms of the improved glycaemic control that is 
frequently observed before the occurrence of significant weight loss following bariatric 
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surgery—a treatment approach that was not seriously considered for type 2 diabetes just a 
few years ago.
Aside from new targets, work continues on additional approaches with existing molecules. 
One aim is to produce an insulin with reduced risk of hypoglycaemia by decreasing 
variability in absorption and action and creating hepatoselective formulations that mimic 
portal insulin activity. More aspirational efforts aim to construct insulin formulations that 
are glucose responsive, with enhanced activity at high glucose and essential but lower 
activity at normal glucose. A different engineering challenge is to modify peptides such as 
GLP-1 and insulin for oral delivery. Automated mechanical devices delivering both insulin 
and glucagon to ‘replace’ the islet are near at hand, but require much refinement to be 
reasonable approaches for type 2 diabetes care [10].
Another expected change in treatment approaches will be a broader use of combination 
therapies. We have already observed this in terms of oral agents that typically combine a 
newer agent with an older one, the latter frequently metformin. Future oral combination 
medications will also probably include two new agents, with one of the first such 
combinations being DPP-4 and SGLT2 inhibitors. We will certainly see triple oral glucose-
lowering medications and a ‘polypill’ that is not solely aimed at lowering glucose. Finally, 
combination therapy will include injectable agents. Development of these has already 
reached the marketplace in combinations of a basal insulin and GLP-1 receptor agonist [11]. 
Animal studies involving new monomeric peptides that have agonistic properties at more 
than a single site have been shown to reduce body weight and improve glycaemia by 
combining activity at GLP-1, glucose-dependent insulinotropic polypeptide (GIP) and 
glucagon receptors [12].
Pragmatic clinical trials
The common approach to testing the effectiveness of medications is the randomised clinical 
trial. In the future, greater use of pragmatic clinical trials for assessing the therapeutic value 
and adverse effect profiles of medications will be employed to enhance the speed and reduce 
the cost of the increasing numbers of trials needed. Such studies require large numbers of 
patients who are broadly representative and therefore could also evaluate effects in patient 
subgroups. Comparative effectiveness research exploring available datasets to elucidate 
treatment responses in populations are emerging today. The future also promises randomised 
comparisons as part of routine care [13].
Personalised medicine—hope created in part by genetics
A development that seems certain in the next 50 years is a greater focus on personalised 
medicine. Clearly, with their hyperglycaemia management guidance [2], the EASD and 
ADA have pointed us in that direction. That said, the rapid advances in genetics, epigenetics 
and metabolomics will surely provide additional targets and tailoring opportunities for 
therapeutic intervention. We should be able to examine an individual’s genetic material and, 
together with their metabolic phenotype, be able to select and monitor optimal agent(s) for 
achieving and maintaining health for extended periods. As we further understand the 
complexities, RNA- and DNA-based therapeutics will certainly emerge.
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Stem cell therapy—a pipe dream?
While the focus of this commentary has been on what to expect in terms of medications, one 
cannot ignore the potential of beta cell replacement therapy. This concept has been the ideal 
for many years, but with the limited number of viable islets and the need for 
immunosuppression, it has been limited to a very few, and the outcomes have not always 
been favourable. An early phase study recently commenced using embryonic stem cell-
derived cells as replacement therapy in type 1 diabetes (ClinicalTrials.gov identifier: 
NCT02239354). Furthermore, the push continues for approaches to convert human 
pluripotent stem cells into beta cells, and a recent report suggested that we may be getting 
closer [14]. However, it must be remembered that such fanfare has greeted many previous 
reports and these have not materialised into game changers. But, with a 50 year timeline, it 
is hard to imagine that the technical hurdles will not be overcome to produce beta cells of 
sufficient quantity and quality, as well as protecting them from the primary disease process.
Concluding remarks
One could argue that we have the technology today to allow people with diabetes or those at 
risk to live normal lifespans free of disabling complications. Certainly, there has been a 
massive failure on a global scale to consistently implement healthy living recommendations, 
provide sufficient patient education/ empowerment, monitor disease progression and 
prescribe adequate pharmaceutical intervention. A large determinant of that failure relates to 
politics and economics, which we must recognise as critical factors. Advances in public 
health sciences and implementation research will be required to blunt the tremendous and 
increasing toll that type 2 diabetes inflicts on individuals and societies [15]. It is up to us to 
ensure that over the next 50 years the expected tremendous advances in our approaches to 
treating and, more importantly, preventing diabetes have the maximum possible impact.
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Currently available glucose-lowering medications and future targets subdivided by the organ 
system in which they have their primary effect. Medications with their general mode of 
action that were developed before 2015 are listed above the organs, while currently 
identified future medications (black text) and targets (red text) with their general mode of 
action are listed below the organs. It is anticipated that over the next 50 years many more 
targets will be identified. CPT1A, carnitine palmitoyltransferase 1A; FGF21, fibroblast 
growth factor 21; FOXO1, forkhead box protein O1; GI, gastrointestinal; HSD11β1, 11β-
hydroxysteroid dehydrogenase type 1; SIRT1, sirtuin 1; PTPN1, protein tyrosine 
phosphatase, non-receptor type 1
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